HC Wainwright Has Bearish Estimate for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Protalix BioTherapeutics in a note issued to investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.05 per share for the year, down from their previous estimate of $0.14. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Separately, Wall Street Zen lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 12th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, Protalix BioTherapeutics presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Protalix BioTherapeutics Price Performance

PLX opened at $1.57 on Wednesday. The business’s 50-day moving average is $1.49 and its two-hundred day moving average is $2.02. Protalix BioTherapeutics has a 1 year low of $0.89 and a 1 year high of $3.10. The firm has a market capitalization of $125.18 million, a PE ratio of -12.08 and a beta of -0.21.

Insider Buying and Selling at Protalix BioTherapeutics

In other news, Director Aharon Schwartz bought 129,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 10th. The shares were purchased at an average cost of $1.60 per share, with a total value of $206,400.00. Following the transaction, the director directly owned 303,000 shares in the company, valued at approximately $484,800. The trade was a 74.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.50% of the stock is owned by company insiders.

Institutional Trading of Protalix BioTherapeutics

Several large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC increased its holdings in shares of Protalix BioTherapeutics by 33.4% in the fourth quarter. Squarepoint Ops LLC now owns 73,940 shares of the company’s stock valued at $139,000 after purchasing an additional 18,522 shares during the period. Northern Trust Corp increased its holdings in Protalix BioTherapeutics by 1,299.4% in the 4th quarter. Northern Trust Corp now owns 731,742 shares of the company’s stock worth $1,376,000 after buying an additional 679,451 shares during the period. Millennium Management LLC raised its position in Protalix BioTherapeutics by 3.8% during the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock worth $729,000 after buying an additional 14,164 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Protalix BioTherapeutics by 147.2% in the 4th quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock valued at $214,000 after acquiring an additional 67,664 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Protalix BioTherapeutics in the fourth quarter worth $192,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.